Distinct mutational status in GATA3-Positive clear cell adenocarcinoma of the urinary tract: A CASE report

Hala Abdelwahab; Derek Friedman; Andrea Lightle; Badar Mian; Hugh Fisher; Mahmut Akgul

doi:10.1016/j.eucr.2021.101793

Distinct mutational status in GATA3-Positive clear cell adenocarcinoma of the urinary tract: A CASE report

Urol Case Rep. 2021 Aug 1:39:101793. doi: 10.1016/j.eucr.2021.101793. eCollection 2021 Nov.

Authors

Hala Abdelwahab¹, Derek Friedman², Andrea Lightle¹, Badar Mian², Hugh Fisher², Mahmut Akgul¹

Affiliations

¹ Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
² Department of Urology, Albany Medical Center, Albany, NY, USA.

Abstract

•Clear cell adenocarcinoma of the lower urinary tract is rare and poses diagnostic challenge.•GATA3, which is frequently expressed in urothelial carcinoma, can be expressed in clear cell adenocarcinoma.•ARID1A, PBRM1, ERBB4, and SMARCA4 mutations were identified in the current CASE.•Molecular studies may aid in the diagnosis, and optimal treatment decision-making process.

Keywords: Bladder; Clear cell adenocarcinoma; Molecular profiling; Urothelial carcinoma.

Publication types

Case Reports